Press

Mydecine Innovations kicks off machine learning-based drug discovery program with the University of Alberta

Jun 17 • 2 min read

Quick Take: Mydecine has launched its machine learning drug discovery program at the University of Alberta. The program will enable the company to more rapidly screen hundreds of thousands of new molecules without the need to produce them, allowing Mydecine to focus on the strongest potential therapeutics Mydecine Innovations Group Inc (NEO:MYCO) has launched its in-silico…

MindMed Appoints Pharmaceutical Veteran Peter Bergethon, M.D. to Scientific Advisory Board

Jun 17 • 4 min read

Quick Take: MindMed has appointed Dr, Peter Bergethon to their scientific advisory board. Dr. Bergethon is an expert in neurology, digital medicine, and CNS drug development. MindMed (NASDAQ: MNMD), a leading biotech company developing psychedelic-inspired therapies, has announced the addition of Dr. Peter Bergethon, a world-leading expert in neurology, digital medicine, and central nervous system (CNS) drug…

CURE Pharmaceutical to Present at H.C. Wainwright 2021 Psychedelics in Psychiatry and Beyond Virtual Conference

Jun 15 • 2 min read

Quick Take: CURE Pharmaceutical’s chief business officer Jonathen Berlent will be speaking at the H.C. Wainwright 2021 Psychedelics in Psychiatry and Beyond conference. CURE Pharmaceutical Holding Corp. (OTC: CURR), a technology focused, vertically integrated drug delivery and product development company in the pharmaceutical and health & wellness markets, announced today that its Chief Business Officer…

Field Trip Health Ltd. Announces Completion of DMPK Studies, Engineering Batch for FT-104, Its Novel Psychedelic Compound

Jun 15 • 3 min read

Quick Take: Field Trip Health has completed its initial metabolism and pharmacokinteic studies of its novel psychedelic compound Field Trip Health Ltd. (TSX: FTRP), a leader in the development and delivery of psychedelic therapies, today announced that it has completed initial drug metabolism and pharmacokinetic (“DMPK”) studies for FT-104, its novel psychedelic compound in development….

Mindset and InterVivo Solutions Announce Availability of First Preclinical Psychedelic Benchmark Data from COPE Program

Jun 14 • 4 min read

Quick Take: Mindset Pharma and InterViro announced the availability of their first data set from their “COPE” program. The COPE program aims to create benchmark data for clinically relevant psychedelic drugs. Mindset Pharma Inc. (CSE: MSET), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441